Close

BIO Announces Gary Andres as the New Senior Executive Vice President of Public Affairs

Long-time Majority Staff Director of the House Energy and Commerce Committee Dr. Gary Andres joins BIO as Senior Executive Vice President of Public Affairs.

Registration Now Open for the 14th Annual BIO World Congress on Industrial Biotechnology

BIO announced registration and housing are now open for the 2017 World Congress on Industrial Biotechnology.  The conference will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Canada. 

BIO Statement on President Trump’s Comments Supporting Biopharmaceutical Competition and Innovation

Washington, DC (January 31, 2017) – BIO issued the following statement regarding President Trump’s comments today supporting biopharmaceutical innovation:

BIO Submits Comments on FDA proposed rule: Good Laboratory Practice for Nonclinical Laboratory Studies

RE: Docket No. FDA-2010-N-0548: The Biotechnology Innovation Organization (BIO) appreciates the opportunity to offer comments to Food and Drug Administration (FDA)’s “Good Laboratory Practice for Nonclinical Laboratory Studies.” 

BIO Statement on USDA and FDA Actions related to Pre-market Regulatory Oversight of Plant and Animal Organisms

The U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) published today four documents related to the pre-market regulatory oversight of a variety of biology-based agricultural tools, including genetically engineered plants and plants and animals derived from certain newer precision breeding techniques, such as genome editing.

BIO’s Jim Greenwood Meets with India’s PM Modi

Delivers Message: India Must Protects Innovators’ Work Product

BIO Statement on Proposed Maryland Drug Pricing Legislation

BIO's statement  regarding proposed drug pricing legislation within the Maryland Senate.

BIO submits comments to Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models

The Biotechnology Innovation Organization appreciates the opportunity to offer comments to the final rule Medicare Program; Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models.

BIO Comments on the National Quality Forum Health and Wellbeing 2015-2017 Report

BIO appreciates the opportunity to comment on the National Quality Forum (NQF) Health and Wellbeing 2015-2017 report.

BIO Submits Comments on FDA Draft Guidance: Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices

Re: Docket No. FDA-2016-N-0001: The Biotechnology Innovation Organization (BIO) is pleased to submit the following comments on the Food and Drug Administration (FDA) Draft Guidance entitled, “Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test (AST) devices”